JP2011505411A - ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン - Google Patents

ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン Download PDF

Info

Publication number
JP2011505411A
JP2011505411A JP2010536457A JP2010536457A JP2011505411A JP 2011505411 A JP2011505411 A JP 2011505411A JP 2010536457 A JP2010536457 A JP 2010536457A JP 2010536457 A JP2010536457 A JP 2010536457A JP 2011505411 A JP2011505411 A JP 2011505411A
Authority
JP
Japan
Prior art keywords
receptor
azabicyclo
phenothiazine
ylmethyl
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010536457A
Other languages
English (en)
Japanese (ja)
Inventor
ティエリー、クレール
クリストフ、プシビルスキ
ジャッキー、ティスヌ‐ベルサイユ
ディディエ、キュサク
Original Assignee
ピエール、ファーブル、メディカマン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン
Publication of JP2011505411A publication Critical patent/JP2011505411A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2010536457A 2007-12-04 2008-12-04 ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン Pending JP2011505411A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0759538A FR2924344B1 (fr) 2007-12-04 2007-12-04 Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
FR0854144A FR2924345B1 (fr) 2007-12-04 2008-06-23 Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
PCT/EP2008/066787 WO2009071625A1 (en) 2007-12-04 2008-12-04 Mequitazine for treating or preventing pathologies involving histamine h4 receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013251130A Division JP2014065726A (ja) 2007-12-04 2013-12-04 ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン

Publications (1)

Publication Number Publication Date
JP2011505411A true JP2011505411A (ja) 2011-02-24

Family

ID=39522380

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010536457A Pending JP2011505411A (ja) 2007-12-04 2008-12-04 ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン
JP2013251130A Pending JP2014065726A (ja) 2007-12-04 2013-12-04 ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013251130A Pending JP2014065726A (ja) 2007-12-04 2013-12-04 ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン

Country Status (22)

Country Link
US (1) US20100273752A1 (es)
EP (2) EP2255811A1 (es)
JP (2) JP2011505411A (es)
KR (1) KR20100108347A (es)
CN (1) CN101883566B (es)
AR (1) AR070673A1 (es)
AU (1) AU2008333220B2 (es)
BR (1) BRPI0820652A2 (es)
CA (1) CA2706898A1 (es)
CL (1) CL2008003584A1 (es)
FR (2) FR2924344B1 (es)
HK (1) HK1148667A1 (es)
IL (1) IL206073A0 (es)
MA (1) MA31930B1 (es)
MX (1) MX2010006139A (es)
NZ (1) NZ586212A (es)
PA (1) PA8805501A1 (es)
RU (1) RU2510273C2 (es)
TN (1) TN2010000241A1 (es)
TW (1) TW200932242A (es)
WO (1) WO2009071625A1 (es)
ZA (2) ZA201004312B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58162588A (ja) * 1982-03-05 1983-09-27 フアルムカ・ラボラトワ−ル メキタジンの圧旋性異性体を含有する抗ヒスタミン剤
JPH06509570A (ja) * 1991-08-07 1994-10-27 ラボラトリ・グイドッティ・エスピーエー （−）および（＋）の１０−（１−アザビシクロ［２．２．２．］オクト−３−イル−メチル）−１０　ｈ−フェノチアジン第４アンモニウム誘導体を有する薬剤組成物およびその製剤プロセス

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
JPS6330420A (ja) * 1986-07-25 1988-02-09 Sekisui Chem Co Ltd 持続性抗アレルギ−固形塗布剤
JP2735122B2 (ja) * 1988-06-13 1998-04-02 旭化成工業株式会社 メキタジンの液状シロップ製剤
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
FR2822709B1 (fr) * 2001-03-30 2007-01-19 Antialis Composition pharmaceutique anti-allergique comprenant au moins un allergene et au moins un compose antihistaminique
DE10158036B4 (de) * 2001-11-27 2007-05-03 Kosmas Kg Antiallergisches Mittel und dessen Verwendung
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
JP2005060233A (ja) * 2003-08-08 2005-03-10 Rohto Pharmaceut Co Ltd 皮膚外用剤
EP1526135A1 (en) * 2003-10-24 2005-04-27 Warner-Lambert Company LLC Azabenzodiazepines as pde4 inhibitors
JPWO2005063253A1 (ja) * 2003-12-26 2007-12-13 大鵬薬品工業株式会社 アレルギー症状治療用医薬組成物
FR2896690B1 (fr) * 2006-01-30 2008-05-02 Pierre Fabre Medicament Sa Utilisation de l'enantiomere(s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58162588A (ja) * 1982-03-05 1983-09-27 フアルムカ・ラボラトワ−ル メキタジンの圧旋性異性体を含有する抗ヒスタミン剤
JPH06509570A (ja) * 1991-08-07 1994-10-27 ラボラトリ・グイドッティ・エスピーエー （−）および（＋）の１０−（１−アザビシクロ［２．２．２．］オクト−３−イル−メチル）−１０　ｈ−フェノチアジン第４アンモニウム誘導体を有する薬剤組成物およびその製剤プロセス

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013026959; 長野準　外２４名: '"気管支喘息患者におけるハウスダスト吸入誘発試験に対するメキタジン錠の効果"' 臨床医薬 Ｖｏｌ．４，Ｎｏ．５, 198805, Ｐ．７３５-７４４, 臨床医薬研究協会 *
JPN6013026962; 須貝哲郎　外５名: '"そう痒を伴う各種皮膚疾患に対するメキタジン（ＭＱ-Ａ８８錠）の臨床効果"' 皮膚 Ｖｏｌ．３１，Ｎｏ．５, 198910, Ｐ．７３３-７４３, 日本皮膚科学会大阪地方会 *
JPN6013026963; 高木繁　外６名: '薬物"塩酸セチリジンのスギ花粉症初期治療効果"' 耳鼻咽喉科臨床 Ｖｏｌ．９３，Ｎｏ．１０, 200010, Ｐ．８７９-８８５, 耳鼻咽喉科臨床学会 *
JPN6014018591; 神尾弘: '"メキタジンの慢性閉塞性肺疾患治療薬としての可能性-イプラトロピウムとの比較-"' 日本呼吸器学会雑誌 Ｖｏｌ．３９，増刊号, 200103, Ｐ．１２９ *

Also Published As

Publication number Publication date
CN101883566A (zh) 2010-11-10
AR070673A1 (es) 2010-04-28
BRPI0820652A2 (pt) 2019-09-10
HK1148667A1 (en) 2011-09-16
EP2255811A1 (en) 2010-12-01
AU2008333220B2 (en) 2014-04-24
TW200932242A (en) 2009-08-01
PA8805501A1 (es) 2009-12-16
WO2009071625A1 (en) 2009-06-11
FR2924345B1 (fr) 2010-06-04
TN2010000241A1 (en) 2011-11-11
AU2008333220A1 (en) 2009-06-11
MA31930B1 (fr) 2010-12-01
FR2924345A1 (fr) 2009-06-05
CA2706898A1 (en) 2009-06-11
NZ586212A (en) 2012-09-28
ZA201004312B (en) 2011-02-23
EP2227235A1 (en) 2010-09-15
FR2924344A1 (fr) 2009-06-05
US20100273752A1 (en) 2010-10-28
KR20100108347A (ko) 2010-10-06
CN101883566B (zh) 2013-03-06
FR2924344B1 (fr) 2010-04-16
JP2014065726A (ja) 2014-04-17
RU2010125711A (ru) 2012-01-10
RU2510273C2 (ru) 2014-03-27
IL206073A0 (en) 2010-11-30
EP2227235B1 (en) 2014-11-12
ZA201007626B (en) 2011-08-31
MX2010006139A (es) 2010-10-15
CL2008003584A1 (es) 2009-05-22

Similar Documents

Publication Publication Date Title
Cazzola et al. Pharmacology and therapeutics of bronchodilators
US8883808B2 (en) Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy
JP7097874B2 (ja) リシルオキシダーゼ様２阻害剤の使用
JP7548669B2 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
JP2002542287A (ja) 医 薬
US20190247373A1 (en) Methods for treating fibrosis
Kistemaker et al. The PDE4 inhibitor CHF-6001 and LAMAs inhibit bronchoconstriction-induced remodeling in lung slices
CA3133422A1 (en) Lipocalin mutein for treatment of asthma
Yuede et al. Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease
JP5727642B2 (ja) センタキンを用いた新規の治療方法
JP2014065726A (ja) ヒスタミンｈ４受容体が関与する病態を治療または予防するためのメキタジン
JP2017507930A (ja) ＩＫＫε／ＴＢＫ１阻害剤とベータアドレナリン作動性アゴニストまたは交感神経系活性化剤との組合せ
JP6698358B2 (ja) 汗分泌促進剤及び該汗分泌促進剤を含有するドライスキンの予防薬又は治療薬
JP2005513105A (ja) 臨床的うつ病を治療するためのデオキシペガニンの使用
JP7577191B2 (ja) フェニルアルキルカルバマート化合物を含むｋｃａ３．１チャネル介在性疾患治療用組成物
JP2004517883A (ja) ヒスタミン受容体アンタゴニスト
JP7433331B2 (ja) 特発性肺線維症を治療するための組成物及び方法
AU2021320511B2 (en) Composition for treating KCA3.1 channel-mediated diseases comprising phenylalkyl carbamate compound
US20180256623A1 (en) Compositions and method for regulating adipose tissue lipolysis, insulin-resistance, and hyperglycemia
US20040138234A1 (en) Histamine receptor antagonists
AU2015363757A1 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141202